Can a pill tailored to inflammation boost red blood cells in kidney disease?

This study tests whether enarodustat, an oral medication, can effectively raise hemoglobin levels in adults with anemia from chronic kidney disease (CKD) who are not on dialysis. Participants will take enarodustat daily, with doses adjusted to reach a target hemoglobin range, and will be grouped by their baseline inflammation levels to see if that affects response. The trial follows each person for 24 weeks, tracking hemoglobin changes, iron metabolism, and any side effects, aiming to find the best dosing strategy for different patients.